Abstract 25P
Background
Epithelial ovarian cancer (EOC) is a disease found mainly in advanced stages and difficult to treat. The study of the expression and methylation of miRNA genes can become the basis for the development of potential new diagnostic and prognostic markers of EOC, as well as the basis for the development of targeted anticancer therapy.
Methods
80 paired samples of EOC (ovarian serous adenocracinoma) were obtained from the National Medical Research Center of Oncology named after N.N. Blokhin. MicroRNA expression was assessed by TaqMan-qPCR with kits from Applied Biosystems, USA. Analysis of methylation of promoter CpG islands of microRNA genes was carried out using bisulfite conversion followed by methyl-specific PCR.
Results
The methylation frequency in the tumor was higher than in paired norm for 10 microRNA genes (MIR-124-1, -124-2, -124-3, -125B-1, -127, -129-2, -132, -137, -193A and -339; p ≤ 5×10-4). ROC analysis showed that a combination of 4 microRNA genes (MIR-124-2, -127, -129-2, -137) can be proposed as a panel of EOC detection markers with sensitivity (Sn) 80%, specificity (Sp) 82 %, AUC=0.86. The combination of miRNA genes (MIR-193A, -129-2, -137) was characterized by Sn=90%, Sp=75% and AUC=0.90. For 5 out of 12 microRNAs studied, a high frequency of reduced expression was observed: miR-125b-5p - in 59% of tumor samples compairing to paired norms, miR-129-5p - in 55%, miR-132-3p - in 55%, miR-137 - in 52% , and miR-193a-5p in 66% (p ≤ 0.05). The correlation of changes in the expression of 12 microRNAs (miR-124-3p, -125b-5p, -127-5p, 129-5p, -132-3p, -137, -148a-3p, -191-5p, -193a-5p, -203a, -339-3p and -375) and changes in methylation of the genes encoding them rs=0.67-0.97 (according to Spearman), p ≤ 10-4.
Conclusions
The role of methylation in the regulation of the expression of 12 microRNAs and the association of the methylation status of 10 microRNA genes with EOC metastasis were revealed. 5 microRNAs downregulated by hypermethylation may find use as potential targets for EOC therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The state task FGFU-2022-0007 of the Ministry of Science and Higher Education of the Russian Federation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Presenter: Radek Spisek
Session: Cocktail & Poster Display session
Resources:
Abstract
3P - Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Presenter: Solange Peters
Session: Cocktail & Poster Display session
Resources:
Abstract
4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
Presenter: Edwin Lin
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Presenter: Jenna Voellinger
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
Presenter: jun Cao
Session: Cocktail & Poster Display session
Resources:
Abstract
7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
Presenter: Bharat Jasani
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
Presenter: Benjamin Sobol
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
Presenter: Yan Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
Presenter: Johnathan Arnon
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
Presenter: Vera Evtimov
Session: Cocktail & Poster Display session
Resources:
Abstract